Received Aug 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
she developed Guillain Barre Syndrome; This serious case was reported by a consumer via interactive digital media and described the occurrence of guillain barre syndrome in a female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included shingles (had twice). Previously administered products included Shingles vaccine (received 1st dose on an unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced guillain barre syndrome (Verbatim: she developed Guillain Barre Syndrome) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome was not reported. The reporter considered the guillain barre syndrome to be related to Shingrix. The company considered the guillain barre syndrome to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 19-JUL-2025 This case was reported by a consumer via interactive digital media. The second one was Shingrix, and she developed Guillain barre syndrome form the vaccine. Now patient had trouble walking and could not take most vaccines. The reporter was 50 but the reporter scared to get it after seeing what it did to her.; Sender's Comments: A case of Guillain-Barre syndrome, an unknown time after receiving Shingrix, in a female patient. Based on the available information, a possible causality that the event(s) was caused by the GSK product cannot be ascertained. Consent for further follow up has not been received.
Medical History/Concurrent Conditions: Shingles (had twice)